OTCMKTS:OSIR - Osiris Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.99 0.00 (0.00 %)
(As of 04/17/2019)
Previous Close$18.99
Today's Range$18.99 - $18.99
52-Week Range$7.01 - $19.30
Average Volume202,293 shs
Market Capitalization$655.69 million
P/E RatioN/A
Dividend YieldN/A
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolOTCMKTS:OSIR
Previous SymbolNASDAQ:OSIR



Sales & Book Value

Annual SalesN/A



Market Cap$655.69 million
Next Earnings DateN/A

Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

Has Osiris Therapeutics been receiving favorable news coverage?

News headlines about OSIR stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Osiris Therapeutics earned a news sentiment score of 1.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of Osiris Therapeutics' key competitors?

What other stocks do shareholders of Osiris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osiris Therapeutics investors own include Sierra Wireless (SWIR), MiMedx Group (MDXG), Achillion Pharmaceuticals (ACHN), Fate Therapeutics (FATE), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), EXACT Sciences (EXAS), Exelixis (EXEL), Novavax (NVAX) and Conatus Pharmaceuticals (CNAT).

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:
  • Mr. Jason Keefer, Interim Pres & CEO (Age 46)
  • Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)
  • Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)
  • Mr. Edward Yip, Chief Legal Officer & Corp. Sec.
  • Mr. Laine Dyess, VP of Sales

Who are Osiris Therapeutics' major shareholders?

Osiris Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alpine Associates Management Inc. (3.57%), Gabelli Funds LLC (1.68%), Renaissance Technologies LLC (1.15%), Cloverdale Capital Management LLC (0.94%), Goldman Sachs Group Inc. (0.79%) and Water Island Capital LLC (0.75%). View Institutional Ownership Trends for Osiris Therapeutics.

Which institutional investors are selling Osiris Therapeutics stock?

OSIR stock was sold by a variety of institutional investors in the last quarter, including Cloverdale Capital Management LLC, Gamco Investors INC. ET AL, Gabelli Funds LLC, Bank of Montreal Can, Wells Fargo & Company MN and Northern Trust Corp. View Insider Buying and Selling for Osiris Therapeutics.

Which institutional investors are buying Osiris Therapeutics stock?

OSIR stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Renaissance Technologies LLC, Goldman Sachs Group Inc., Water Island Capital LLC, Water Island Capital LLC, ARP Americas LP, GABELLI & Co INVESTMENT ADVISERS INC. and Morgan Stanley. View Insider Buying and Selling for Osiris Therapeutics.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of OSIR stock can currently be purchased for approximately $18.99.

How big of a company is Osiris Therapeutics?

Osiris Therapeutics has a market capitalization of $655.69 million.

What is Osiris Therapeutics' official website?

The official website for Osiris Therapeutics is http://www.osiristx.com/.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]

MarketBeat Community Rating for Osiris Therapeutics (OTCMKTS OSIR)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel